Physician profile
Ramin Rahimi
NPI 1639146624
$2,431.96
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was more than what 78% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $125 · 2021: $386 · 2022: $492 · 2023: $566 · 2024: $256 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.78 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $207.60 | 2023-2025 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $178.33 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Ibsa Pharma INC. | $166.03 | 2022 | |
| Averitas Pharma INC. | $154.00 | 2023-2024 | Qutenza |
| Merz North America, INC. | $152.03 | 2025 | |
| Ferring Pharmaceuticals INC. | $86.22 | 2019-2023 | Euflexxa |
| Pfizer INC. | $83.87 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $70.24 | 2021 | |
| Lilly USA, LLC | $68.15 | 2020-2022 | |
| Horizon Therapeutics Plc | $66.52 | 2019-2022 | |
| Amgen INC. | $65.08 | 2020-2021 | |
| Braeburn INC. | $59.80 | 2023-2025 | Brixadi |
| Allergan, INC. | $54.02 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.86 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $48.67 | 2024 | |
| Avanir Pharmaceuticals, INC. | $47.17 | 2022 | |
| Novo Nordisk INC | $38.81 | 2019 | |
| Depuy Synthes Sales INC. | $35.39 | 2023-2024 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $28.20 | 2025 | |
| Biodelivery Sciences International, INC. | $27.84 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.94 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $20.80 | 2023 | Nuedexta |
| Boston Scientific Corporation | $19.74 | 2021 | |
| Bioventus LLC | $13.65 | 2021 | |
| Orexo US, INC. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Rahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.